Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 6/20 | 1.00 |
| ▸ | P2RX2 | Q9UBL9 | 6/20 | 1.00 |
| ▸ | DHFR | P00374 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1493976 | 1.00 | P2RX3 (1.00) | P2RX3P2RX2DHFR | |
| SCHEMBL1493951 | 0.90 | P2RX3 (0.82) | P2RX3P2RX2DHFR | |
| SCHEMBL30215842 | 0.90 | P2RX3 (0.82) | P2RX3P2RX2DHFR | |
| SCHEMBL1494148 | 0.89 | P2RX3 (0.80) | P2RX3P2RX2DHFR | |
| SCHEMBL30215897 | 0.89 | P2RX3 (0.80) | P2RX3P2RX2DHFR | |
| SCHEMBL1493991 | 0.89 | P2RX3 (0.92) | P2RX3P2RX2DHFR | |
| SCHEMBL30215839 | 0.89 | P2RX3 (0.92) | P2RX3P2RX2DHFR | |
| SCHEMBL18712629 | 0.87 | P2RX3 (0.76) | P2RX3P2RX2DHFR | |
| SCHEMBL13842542 | 0.86 | P2RX3 (0.75) | P2RX3P2RX2DHFR | |
| SCHEMBL18712627 | 0.86 | P2RX3 (0.74) | P2RX3P2RX2DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066309-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2025-02-27 | — | — | US | disclosed |
| US-20250025462-A1 | METHODS OF USING DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES | ROCHE PALO ALTO LLC (US) | 2025-01-23 | — | — | US | disclosed |
| US-20230100975-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2023-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066309-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX6, P2RX2 | P2RX3 1/4885P2RX2 3/4885DHFR 1126/4885 |
| US-20230100975-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX6, P2RX2 | P2RX3 1/4885P2RX2 3/4885DHFR 1126/4885 |
| US-20250025462-A1 | METHODS OF USING DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES | P2RX3, P2RX2, P2RX1 | P2RX3 1/4885P2RX2 2/4885DHFR 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.